Please ensure Javascript is enabled for purposes of website accessibility

Why Elanco Animal Health's Q4 Results Didn't Have Much Bite

By Keith Speights – Feb 19, 2020 at 2:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The animal-health company posted lower-than-expected revenue in Q4.

Most stocks delivered tremendous gains in 2019 -- but not Elanco Animal Health (ELAN -3.73%). The stock fell by nearly 7% last year and its early momentum in 2020 has now largely fizzled out.  

Elanco announced its 2019 fourth-quarter and full-year results before the market opened on Wednesday. Unfortunately, those results didn't give investors a reason to be tremendously enthusiastic about the company's prospects. Here are the highlights from Elanco's Q4 update.

Woman hugging her two dogs

Image Source: Getty Images.

By the numbers

Elanco's top-line performance went in the wrong direction in the fourth quarter. Revenue fell 2% year over year to $787 million. This result was also below the consensus Wall Street Q4 revenue estimate of $791.5 million.

The company reported a net loss in the fourth quarter of $9.5 million, or $0.03 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, the company announced GAAP net income of $16.4 million, or $0.04 per share.

On a non-GAAP adjusted basis, Elanco's net income in the fourth quarter was $87.8 million, or $0.23 per share. This reflected a 17% year-over-year decline. However, Elanco's Q4 adjusted earnings per share (EPS) met the average analyst's adjusted EPS estimate for the quarter.

Behind the numbers

Elanco's largest business in terms of sales is its food animal unit. Total food animal revenue increased by 1.4% year over year in Q4 to $509.1 million. This modest growth was primarily driven by price increases, although the company also saw some increased volume for its ruminants and swine products, especially Posilac, a drug that improves milk productivity in cows. 

However, Elanco's food animal business experienced some challenges in the fourth quarter. Changing policies in Asia weighed on revenue, as did the impact of African Swine Fever in Asia. In addition, U.S. producers reduced their purchases of Paylean, a drug that helps build muscle in show pigs.

There was good news and bad news in Q4 for Elanco's companion-animal business. Companion-animal therapeutics revenue jumped 33% year over year, driven largely by higher sales for canine arthritis drug Galliprant. But companion-animal disease prevention revenue fell 15% from the prior-year period, primarily due to several factors that boosted sales in the fourth quarter of 2018. Overall, Elanco's companion-animal revenue fell 2.2% year over year to $266.6 million.

Looking ahead

Elanco continues to project sales of between $3.05 billion and $3.11 billion for full-year 2020. The company expects earnings per share (EPS) will be between $0.04 and $0.16, with adjusted EPS between $1.09 and $1.16.

Probably the biggest development to look forward to with Elanco is its acquisition of Bayer Animal Health. Elanco CEO Jeff Simmons said that the "transaction is developing better than we expected when we announced in August of 2019." Elanco expects to close the acquisition in mid-2020.

While many healthcare stocks could experience turbulence this year with the U.S. presidential election heating up, animal health stocks like Elanco shouldn't be impacted very much by the political dynamics.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Elanco Animal Health Incorporated Stock Quote
Elanco Animal Health Incorporated
$12.66 (-3.73%) $0.49
Bayer Stock Quote
$11.72 (-0.51%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.